About
Corporate Overview
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
Platform
Critical Limb Ischemia
Investors
Investor Overview
A Three Minute Summary
Public Filings
AGM Materials
News & Media
News / Press Releases
Contact
MENU ≡
About
Corporate Overview
Management
Scientific Advisory Board
Board of Directors
Board of Advisors
Partnerships
Technology
Technology Overview
Manufacturing
Intellectual Property
Publications
Clinical Pipeline
ACP-01 Phase II Clinical Trial for CLI
Platform
Critical Limb Ischemia
Investors
Investor Overview
A Three Minute Summary
Public Filings
AGM Materials
News & Media
News / Press Releases
Contact
Contact
Thomas A. Smeenk, BA
President & CEO, Co-Founder
Hemostemix Inc. TSXV:HEM
905-580-4170
tsmeenk@hemostemix.com
